X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Legal pressure is rising to force drug makers to disclose all studies, good or bad, that shed light on the safety of medicines they sell. On June 2, New York State Attorney General Eliot Spitzer charged GlaxoSmithKline with concealing data about the safety of its antidepressant Paxil. His suit appears to be the first to argue that a drug maker’s failure to publicize negative safety data constitutes fraud. New York v. GlaxoSmithKline PLC, No. 04-401707. A Glaxo spokeswoman objected to the premise of Spitzer’s case, saying her company disclosed the data to regulatory agencies. Yet doctors most likely couldn’t learn about the safety findings. The Food and Drug Administration generally treats data submitted by drug makers as proprietary. Even if Glaxo’s argument works in court to rebuff Spitzer, another lawsuit filed in February in Washington aims to end drug makers’ practice of treating the regulatory process as a shelter. This case, filed by the nonprofit group Public Citizen, has already succeeded in extracting evidence of safety risks for a popular medicine that Pfizer sells as Bextra. The Spitzer and Public Citizen cases signal that drug companies may need to reassess how they talk to regulators, and that lawyers are likely to play a prominent role in these discussions. The effort to expose the Bextra data was launched after the manufacturer announced that it had asked the FDA to approve Bextra for four purposes. The FDA approved three, rejecting it as a treatment for acute pain. Then a journal published an article concluding that Bextra did help fight pain, and Public Citizen asked the FDA for the evidence that persuaded it to reject Bextra for pain treatment. At first, the FDA gave to Public Citizen material that hid the safety data as confidential. After the group filed suit, the FDA partially reconsidered, revealing that Bextra wasn’t approved in part because it had caused heart trouble in some patients who were given it for pain. Public Citizen has filed several suits over whether safety studies are confidential business information. The manufacturers won a round in 1999, when a court ruled that safety data may remain confidential if attached to an abandoned drug candidate. The logic: Revealing this failure may give competitors an advantage by helping them avoid mistakes. Public Citizen lawyer Allison Zieve said that with a product already on the market, such confidentiality is even less justifiable. The drug makers face limited choices on how to keep information confidential. “The result can’t be that they stop submitting the information,” said Philip Katz of Washington-based Crowell & Moring. Rather than addressing how to interact with regulators, said Arnold & Porter partner William Vodra, “Lawyers will get involved in a different set of questions: Do you want to do this study?”

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.